Format

Send to

Choose Destination
Gene. 2015 Jul 1;565(1):140-5. doi: 10.1016/j.gene.2015.04.001. Epub 2015 Apr 2.

Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.

Author information

1
Department of Medical Genetics, Mayo Clinic, Rochester, MN 55905, USA; Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: deyle.david@mayo.edu.
2
Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
3
Department of Medical Genetics, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: dbabovic@mayo.edu.

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are devastating soft tissue sarcomas that can arise sporadically or in association with neurofibromatosis type I, have a poor prognosis, and have limited treatment options. Oncolytic measles virus therapy has been demonstrated to have significant antitumor properties in a number of different cancers, but the oncolytic potential of a MV Edmonston (MVEdm) vaccine strain engineered to express the human sodium iodide symporter (MV-NIS) on MPNST has not previously been evaluated. MPNST cell lines were found to highly express CD46, a cellular receptor required for measles viral entry, on their cell surface. After in vitro MV-NIS infection, MPNST cell lines showed significant cytopathic effect (CPE), while normal Schwann cells were less susceptible to CPE. Virus localization and distribution could be monitored by imaging of I-125 uptake. Local administration of MV-NIS into MPNST-derived tumors resulted in significant regression of tumor and improved survival. These results demonstrate feasibility of oncolytic measles virus therapy for MPNST patients and the possibility of a novel treatment for patients with NF1 tumors.

KEYWORDS:

Malignant peripheral nerve sheath tumor; Measles virus; Oncolytic therapy

PMID:
25843626
DOI:
10.1016/j.gene.2015.04.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center